Not provided
Not provided
Not provided
Not provided
commercial reason
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Astex Pharmaceuticals, Inc. | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is a two strata Phase 1b study to assess the safety and efficacy of bisantrene (RC110) in combination with a) cytarabine arabinoside (Ara-C) treatment for patients with relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) with extramedullary disease and able to tolerate intensive chemotherapy; b) in combination with decitabine/cedazuridune (ASTX727) new or relapsed or refractory AML or high risk MDS or CMML with extramedullary disease and unable or not willing to have intensive chemotherapy.
The study is a multicenter, open label in patients with haematological malignancy / myeloproliferative disease (AML, MDS and CMML) and extramedullary disease (EMD) investigating 2 treatment regimens:
Pre-screening will be conducted to identify patients with EMD diagnosed by standard clinical practice including histology and by fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F FDG-PET/CT) imaging.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Stratum 1 | Experimental | Bisantrene infused daily for 7 days of induction cycle 1; followed by bisantrene infusion on Days 1 and 2 and cytarabine arabinoside continuous infusion on Days 1 to 5 of each consolidation cycle for up to 3 cycles. Each cycle is 28 days, with a potential to expand to 42 days to allow for full hematologic recovery. |
|
| Stratum 2 | Experimental | Decitabine/cedazuridine daily on Days 1-5, Bisantrene infusion on Days 3 and 5 in 28 day cycle. Treatment repeats every 28 days up to 12 cycles in the absence of disease progression or unacceptable toxicity. Each has potential to expand to 42 days to allow for full hematologic recovery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Bisantrene Dihydrochloride (high dose) | Drug | Induction monotherapy cycle: IV bisantrene daily on Days 1 to 7, starting at 250 mg/m2 then adjusted to either 275 mg/m2 or 225 mg/m2 based on confirmed dose (Run-in) Consolidation combination cycle/s: IV bisantrene daily on Days 1 to 2 |
| Measure | Description | Time Frame |
|---|---|---|
| Stratum 1, Stage 1: Dose confirmation | Maximum tolerated dose (MTD) based on occurence dose limiting toxicity (DLT) graded according to the National Cancer Institute Common Terminology Criteria (NCI CTCAE) for Adverse Events v5.0 after completion of 2 cycles of treatment | 8 weeks |
| Stratum 1 Stage 2: Overall response | Morphological overall response, defined as complete remission (CR), CR with incomplete hematologic recovery or morphologic leukemia free state (MLFS), after completion of first treatment cycle 1 | 4 weeks |
| Stratum 2: Safety and tolerabillity | Assessed based on the occurence of non-hematological Dose limiting toxicity (DLT) as graded according to the National Cancer Institute Common Terminology Criteria (NCI CTCAE) for Adverse Events v5.0 at the completion of cycle 1. | 4 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Stratum 1: Minimal Residual Disease (MRD) response | Response is defined as MRD negativity with and without morphological complete remission (CR), at low level molcular MRD with CR and MRD relapse (coversion MRD negativity to positivity) at the completion of cycle 1 | 4 weeks |
| Stratum 1: Radiologic response |
Not provided
Inclusion Criteria:
[Both Stratums]
Patients must be able to understand and provide informed written consent.
Patients must be of age ≥ 18 years at the time of signing the informed consent.
Extramedullary disease (i.e., AML) by 18F-FDG PET/CT and/or clinical morphology (histopathology of chloroma, leukemia cutis or AML) at pre-screening
Patients who have undergone stem cell transplantation (SCT), maybe included if they are ≥ 8 weeks from stem cell infusion (autologous or allogeneic), have no active graft versus host disease (GVHD), are off immune suppression for at least 2 weeks, and do not have a history of veno occlusive disease (VOD).
Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.0 for intensive Stratum 1 patients and ≤ 3.0 for low intensity treatment Stratum 2 patients.
Life expectancy estimated to be > 3 months.
Adequate organ function as evidenced by serum total bilirubin ≤ 2.0 mg/dL, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 × the upper limit of normal (ULN), serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance of ≥ 60 mL/min.
Cardiac ejection fraction ≥ 50%, assessed by 2-Dimensional (2D) echocardiogram.
Females of childbearing potential must have a negative serum pregnancy test at enrolment or within 14 days before study entry and must agree to use an adequate method of contraception, i.e., barrier method, during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception, i.e., barrier method, during the study until 30 days after the last treatment.
[Stratum 1 only]
Diagnosis of R/R AML, defined as ≥ 5% blasts in a patient with known prior history of AML according to World Health Organization (WHO) criteria. Patients with AML that have relapsed at least once or are primary induction failure will be eligible.
[Stratum 2 only]
Patients with diagnosis of de novo AML with EMD, or R/R AML with EMD.
Patients with MDS or CMML, diagnosed according to the 2016 WHO classification with high-risk disease per the International Prognostic Scoring System (IPSS) of intermediate 2 or higher for both MDS and CMML. Revised IPSS intermediate risk patients can be considered after discussion with the Investigator.
Exclusion Criteria:
[Both Stratums]
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marinella Messina, PhD | Clinical Director | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Calvary Mater | Newcastle | New South Wales | 2298 | Australia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Bisantrene Dihydrochloride (low dose) | Drug | IV bisantrene at escalating doses for 3 dose levels of 50, 65, 85 mg/m2 on Days 3 and 5 until Maximum tolerated dose (MTD) reached. |
|
|
| Cytarabine Hydrochloride | Drug | Consolidation cycles: continuous IV cytarabine (100mg/m2) on Days 1 to 5 |
|
|
| Decitabine and cedazuridine | Drug | PO fixed-dose decitabine/cedazuridine 35/100 mg tablet daily for 5 days (Days 1 to 5), 1 hour prior bisantrene infusion |
|
|
Response evaluation by 18F-FDG-PET/CT is based on the 5-point scale Deauville criteria for complete metabolic response (defined as Deauville Score (DS) 1, 2, or 3) or for partial metabolic response (defined DS of 4 or 5 with decrease in number or activity in bone marrow/EMD disease at the completion of cycles 1,2 and 4.. |
| 4, 8 and 16 weeks |
| Stratum 1: Dermal clinical response | Dermal response based on improvement on the static investigator global assessment (IGA) 5-point disease severity scores, where higher score indicate more disease, defined as decrease of at least two points relative to baseline at the completion of cycles 1,2 3 and 4. | 4, 8, 12, and 16 weeks |
| Stratum 1: Dermal therapeutic response | Dermal therapeutic improvement based on the static investigator global assessment (IGA) 5-point disease severity scores, where higher score indicate more disease, defined as decrease of at least two points relative to baseline at the completion of cycles 1,2 3 and 4. | 4, 8, 12, and 16 weeks |
| Stratum 1: Safety and tolerability | Safety and tolerability based on the incidence and severity of adverse events assessed using National Cancer Institute-Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0, grade per event, patient, and cycle of treatment. | 4, 8, 12 and 16 weeks |
| Stratum 1: Number of participants that recieve subsequent allogeneic hematopoietic stem cell transplant | Proportion of patients who receive subsequent allogeneic HSCT | 5 years |
| Stratum 1:Event free survival (EFS) | EFS assessed between treatment start until the date of the earliest of these events: death, progression or off protocol-treatment for any reason using the Kaplan-Meier method | Day 1 (treatment start) to 5 years |
| Stratum 1: Overall Survival (OS) | OS assessed between treatment start until death due to any cause using the Kaplan-Meier method | Day 1 (treatment start) to 5 years |
| Stratum 2: Overall response | Morphological overall response, defined as either CR or CR as complete remission (CR), CR with incomplete hematologic recovery, CR with incomplete count recovery or MLFS. For patients with MDS/CMML, overall response, defined as either CR or modified CR mCR with haematological improvement (HI) at the end of cycle 1 | 4 weeks |
| Stratum 2: Minimal Residual Disease (MRD) response | Response is defined as MRD negativity with and without morphological complete remission (CR), at low level molecular MRD with CR and MRD relapse (coversion MRD negativity to positivity) at the completion of cycle 4. | 16 weeks |
| Stratum 2: Radiologic response | Response evaluation by 18F-FDG-PET/CT, based on the 5-point scale Deauville criteria for complete metabolic response (defined as as Deauville Score (DS) 1, 2, or 3) or for partial metabolic response (defined as DS of 4 or 5 with decrease in number or activity in bone marrow/EMD disease) at the the completion of cycles 4, 6, 9 and 12 | 16, 36 and 48 weeks |
| Stratum 2: Dermal clinical response | Dermal clinical improvement based on the static investigator global assessment (IGA) 5-point disease severity scores, where higher score indicate more disease, defined as as disease severity score of 1 (almost clear) or 0 (clear) and at least a two grade/point decrease in severity score relative to baseline the completion of cycles 4, 6, 9 and 12 | 4, 24, 36 and 48 weeks |
| Stratum 2: Dermal therapeutic response | Dermal therapeutic improvement based on the static investigator global assessment (IGA) 5-point disease severity scores, where higher score indicate more disease, defined as decrease of at least two points relative to baseline the completion of cycles 4, 6, 9 and 12. | 4, 24, 36 and 48 weeks |
| Stratum 2: Event free survival (EFS) | EFS assessed between treatment start until the date of the earliest of these events: death, progression or off protocol-treatment for any reason assessed | Day 1 (treatment start) up to 5 years |
| Stratum 2: Overall survival (OS) | OS assessed between treatment start until death due to any cause using the Kaplan-Meier method | Day 1 (treatment start) to 5 years |
| ID | Term |
|---|---|
| D015470 | Leukemia, Myeloid, Acute |
| D015477 | Leukemia, Myelomonocytic, Chronic |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D054437 | Myelodysplastic-Myeloproliferative Diseases |
| D001855 | Bone Marrow Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C031404 | bisantrene |
| D003561 | Cytarabine |
| D001085 | Arabinofuranosylcytosine Triphosphate |
| C000723076 | decitabine and cedazuridine drug combination |
| ID | Term |
|---|---|
| D003562 | Cytidine |
| D011741 | Pyrimidine Nucleosides |
| D011743 | Pyrimidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D001087 | Arabinonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
| D003597 | Cytosine Nucleotides |
| D011742 | Pyrimidine Nucleotides |
| D001088 | Arabinonucleotides |
| D009711 | Nucleotides |
Not provided
Not provided